Latest Manufacturing Capacity News

Clarity Pharmaceuticals is approaching pivotal Phase III readouts for its prostate cancer imaging agent, backed by AUD178.3 million in liquid assets. The radiopharmaceutical developer remains deeply loss-making, but expanded manufacturing capacity and early clinical signals are pulling its commercial ambitions into sharper focus.

KTEK Aerosystems has restarted deliveries under its principal production program, with an initial batch ready for collection from its European manufacturing network. The company has also lifted stated monthly manufacturing capacity to 200 units, although future revenue remains dependent on output, acceptance and logistics.

Firebrick Pharma has approved a phased push into US retail pharmacies after Nasodine online sales grew by more than 200% in FY26. Up to six regional pharmacy groups representing about 700 stores have expressed strong interest in early orders, although no binding orders have been disclosed.

Structural Monitoring Systems (ASX:SMN) delivered record FY26 revenue, a sharp lift in profit and $6.0 million of free cash flow as its avionics business outpaced contract manufacturing. The balance sheet is now free of bank debt, but the next leg of the story still depends on FAA approvals and converting CVM technology into commercial revenue.

Mesoblast has secured FDA approval to add a new potency assay to commercial release and stability testing for Ryoncil, its approved cell therapy for paediatric graft-versus-host disease. The regulatory decision supports tighter monitoring as manufacturing processes evolve, but the company disclosed no direct financial impact or clinical outcome data.

Waterco Limited (ASX:WAT) delivered record FY26 EBIT of $23.8 million and lifted net profit after tax 59.6% to $15.4 million, despite only modest revenue growth. The stronger result supports a higher fully franked dividend, but the group is carrying more debt and inventory as it expands manufacturing capacity.

Innovaero Technologies is seeking A$40 million through a proposed ASX listing to advance its OWL loitering munition program and expand manufacturing capacity. The replacement prospectus also makes clear that the company remains loss-making and heavily dependent on the Department of Defence converting development work into production orders.

PolyNovo delivered 16.1% revenue growth and a sharp improvement in operating cash flow in FY26, despite a lower statutory profit after a prior-year tax benefit and a fire-related write-off. The ASX-listed wound-care company now expects to lodge its U.S. PMA application for NovoSorb BTM before the end of 2026.

Green360 Technologies says more than 3,500 cubic metres of concrete containing its MKX metakaolin product has now been used across major Melbourne infrastructure projects. The milestone gives the company a growing field record while it develops demand before committing to dedicated large-scale production.

Telix’s Pixclara has become the first FDA-approved FET-PET imaging drug for glioma, opening a new US diagnostic pathway for adults and children. The approval is commercially significant, but pricing, reimbursement and launch timing remain undisclosed.

Phoslock Environmental Technologies has advanced a new range of lanthanum-enhanced phosphorus-binding products showing up to four times the capacity of current offerings, with pilot and manufacturing tests confirming strong performance and low lanthanum release. Field trials are underway, aiming for commercial sales in 2027.

The Calmer Co International Limited has closed a renounceable rights issue, raising $1.82 million before costs with full director participation. The capital will support inventory build, retail expansion with Coles, and ongoing strategic partnerships in kava supply and manufacturing.